Given the prevalence of super-enhancer dysregulation in cancer, inhibition of super-enhancer-driven gene expression has become a popular therapeutic strategy, with drugs targeting BRD4 and CDK7 [131,132,133] being developed for anticancer therapies. This evidence concerns the gene BRD4 and cancer.